MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
59.47
+0.57
+0.97%
After Hours: 59.47 0 0.00% 19:30 09/11 EDT
OPEN
60.07
PREV CLOSE
58.90
HIGH
60.20
LOW
58.21
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
65.00
52 WEEK LOW
30.81
MARKET CAP
8.85B
P/E (TTM)
-7.7887
1D
5D
1M
3M
1Y
5Y
1D
Vaxcyte (PCVX) On Tighter Phase 3 Timing And New Hires Looks Undervalued
Simply Wall St · 17h ago
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
The Motley Fool · 4d ago
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
The Motley Fool · 4d ago
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The Motley Fool · 4d ago
Weekly Report: what happened at PCVX last week (0831-0904)?
Weekly Report · 5d ago
Vaxcyte narrows timing for pivotal VAX-31 data to late October
Seeking Alpha · 6d ago
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX)
Simply Wall St · 6d ago
Vaxcyte Appoints Luis Jodar, David McAvoy To Leadership Team; Accelerates Phase 3 VAX-31 Timeline
NASDAQ · 09/04 07:53
More
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.